Michael Mauro, MD
Hematology · New York, NYNPI 1609884188
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $143,949 of the $228,992 with a category attached, or 62.9%. 7 manufacturers reported payments, led by Novartis at 52.8% of the total. Reporting peaked in 2019 at $83,838 and has fallen 69.5% since, to $25,603 in 2025. Among hematology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 112 payments — averaging $2044.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$121K
- Novartis Pharma AG$41K
- E.r. Squibb & Sons, L.L.C.$30K
- Takeda Pharmaceuticals U.S.A., Inc.$16K
- Pfizer$16K
- AbbVie$5K
- plus $24 from 1 others
Across 68 payments — averaging $510,169 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$34.5M
- E.r. Squibb & Sons, L.L.C.$110K
- Takeda Pharmaceuticals U.S.A., Inc.$17K
- Pfizer$16K
- Novartis Pharma AG$2K
What the payments were for
- Consulting fees$143,94963%
- Speaking & faculty fees$17,4578%
- Travel & lodging$60,67826%
- Food & beverage$2,2371%
- Education$4,6712%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 47 | $120,803 |
| Novartis Pharma AG | 18 | $40,581 |
| E.r. Squibb & Sons, L.L.C. | 23 | $29,873 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $16,395 |
| Pfizer(2 entities) | 8 | $15,917 |
| AbbVie | 4 | $5,400 |
| Incyte Corporation | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$228,992 in reported general payments places this provider in the 95th percentile of 157 hematology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 113 | $1,421,360 |
| OjjaaraMomelotinib Dihydrochloride | 39 | $1,375,276 |
| ScemblixAsciminib Hydrochloride | 54 | $1,140,092 |
| VonjoPacritinib Citrate | 24 | $570,675 |
| SprycelDasatinib | 37 | $349,404 |
| BosulifBosutinib | 15 | $226,248 |
| PegasysPeginterferon Alfa-2a | 16 | $72,850 |
| Imatinib Mesylate | 17 | $22,629 |
| Hydroxyurea | 100 | $2,535 |
| Allopurinol | 57 | $663 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $24 | $1,421,360113 claims |
| NovartisScemblix | $120,803 | $1,140,09254 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $29,873 | $349,40437 claims |
| PfizerBosulif | $15,917 | $226,24815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 157 hematology providers in New York.
Other hematology in New York
- Barry CollerNew York$7.9M
- Allyson OceanNew York$1.4M
- Ahmed SawasNew York$618K
- Jeffrey ZwickerNew York$561K
- Dan DouerNew York$477K
- Ran ReshefNew York$468K
- Faith DaviesNew York$307K
- Richard FurmanNew York$208K
- Ann JakubowskiNew York$123K
- Adam KittaiNew York$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.